Compare · ABT vs DNTH
ABT vs DNTH
Side-by-side comparison of Abbott Laboratories (ABT) and Dianthus Therapeutics Inc. (DNTH): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both ABT and DNTH operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- ABT is the larger of the two at $200.95B, about 32.0x DNTH ($6.27B).
- DNTH has been more active in the news (16 items in the past 4 weeks vs 8 for ABT).
- ABT has more recent analyst coverage (25 ratings vs 14 for DNTH).
- Company
- Abbott Laboratories
- Dianthus Therapeutics Inc.
- Price
- -
- -
- Market cap
- $200.95B
- $6.27B
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NYSE
- NASDAQ
- IPO
- 2018
- News (4w)
- 8
- 16
- Recent ratings
- 25
- 14
Abbott Laboratories
Abbott Laboratories discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The Established Pharmaceutical Products segment provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon. The Diagnostic Products segment offers laboratory systems in the areas of immunoassay, clinical chemistry, hematology, and transfusion; molecular diagnostics systems that automate the extraction, purification, and preparation of DNA and RNA from patient samples, as well as detect and measure infectious agents; point of care systems; cartridges for testing blood; rapid diagnostics lateral flow testing products; molecular point-of-care testing for HIV, SARS-CoV-2, influenza A and B, RSV, and strep A; cardiometabolic test systems; drug and alcohol test, and remote patient monitoring and consumer self-test systems; and informatics and automation solutions for use in laboratories. The Nutritional Products segment provides pediatric and adult nutritional products. The Medical Devices segment offers rhythm management, electrophysiology, heart failure, vascular, and structural heart devices for the treatment of cardiovascular diseases; and diabetes care products, as well as neuromodulation devices for the management of chronic pain and movement disorders. The company was founded in 1888 and is based in North Chicago, Illinois.
Latest ABT
- Abbott receives FDA authorization for world's first dual glucose-ketone sensing technology for people with diabetes
- Abbott Laboratories filed SEC Form 8-K: Regulation FD Disclosure, Other Events, Financial Statements and Exhibits
- Abbott reaches agreements to resolve a portion of litigation involving its specialty formulas for preterm infants
- Abbott and NACHC launch nationwide Food for Health initiative to make nutritious food a core part of healthcare
- EXECUTIVE VICE PRESIDENT Morrone Louis H. sold $642,506 worth of Common shares without par value (5,850 units at $109.83), decreasing direct ownership by 8% to 70,724 units (SEC Form 4)
- Abbott Labs upgraded by Wolfe Research with a new price target
- Abbott and Big Ten bring back 'We Give Blood' as U.S. faces blood supply crisis
- Abbott and Google launch first-of-its-kind partnership to transform everyday health through glucose insights and AI
- SEC Form 10-Q filed by Abbott Laboratories
- FDA Approves Freenome’s SimpleScreen™ CRC Blood-Based Screening Test; Abbott to Commercialize in the U.S.
Latest DNTH
- Director Read Simon sold $326,554 worth of shares (2,778 units at $117.55) as part of a pre-agreed trading plan and exercised 2,778 shares at a strike of $18.36 (SEC Form 4)
- SVP, General Counsel and Sec. Veness Adam M exercised 15,000 shares at a strike of $18.17 (SEC Form 4)
- SEC Form SCHEDULE 13G filed by Dianthus Therapeutics Inc.
- Director Mcgeorge Anne exercised 7,750 shares at a strike of $12.52 and sold $844,822 worth of shares (7,750 units at $109.01) as part of a pre-agreed trading plan (SEC Form 4)
- Director Read Simon exercised 2,777 shares at a strike of $18.36 and sold $304,232 worth of shares (2,777 units at $109.55) as part of a pre-agreed trading plan (SEC Form 4)
- SVP, General Counsel and Sec. Veness Adam M sold $2,208,833 worth of shares (20,000 units at $110.44) as part of a pre-agreed trading plan and exercised 20,000 shares at a strike of $17.88 (SEC Form 4)
- SEC Form 144 filed by Dianthus Therapeutics Inc.
- Agomab Announces Proposed Appointments of Marino Garcia and Dr. Naimish Patel to Board of Directors
- CEO AND PRESIDENT Garcia Marino exercised 166,000 shares at a strike of $8.44 and sold $17,945,451 worth of shares (166,000 units at $108.11) as part of a pre-agreed trading plan (SEC Form 4)
- SEC Form 144 filed by Dianthus Therapeutics Inc.